Business
CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical
CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical.
About this update from Cardiac Biotech Solutions Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical\r\n \r\n \r\n\r\n\r\nCBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical\r\n\r\n\r\n\r\n\r\n\r\nLAS VEGAS, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) (\"CBSC\" or the \"Company\"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the receipt of an initial purchase order from Noventis Medical, its exclusive Central America distribution partner, for the supply of 2,500 MyCardia AT Cardiac Event Monitoring devices. The total order value is $375,000 USD based on a per-unit price of $150. Under the terms of the agreement, 1,000 devices will be shipped immediately upon completion of production, with the remaining 1,500 units to be delivered within 90 days. “This purchase order not only reinforces market demand for the MyCardia AT but also marks the beginning of a sustainable, long-term revenue model,” said Charles Martin, Chief Executive Officer of CBSC. “By combining device sales with recurring software-driven rental fees, we believe that we are positioned to deliver consistent value for both our healthcare partners and our shareholders.” In addition to upfront device sales, CBSC has implemented a recurring monthly rental program to generate ongoing revenue from devices once deployed in hospitals and healthcare facilities. This program covers the use of each device, the AWS Cloud-based monitoring software, and patient-facing smartphone applications. Revenue from the monthly rental program is shared between CBSC and its distributor partners, with CBSC receiving one-third of the monthly fee and the distributor retaining the balance. Pricing varies by country, reflecting regional healthcare economics and reimbursement practices. The Company continues to advance the global commercialization of its MyCardia AT cardiac event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the United States and additional submissions progressing in Canada and China, this newest international agreem...